Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Predilife S.A. is a biotechnology company operating within the healthcare sector. It focuses on predictive medicine, which involves assessing individual health risks and potential disease outcomes through advanced statistical approaches and data analysis. The company offers innovative solutions aimed at improving early detection and prevention strategies for various diseases, particularly those that are life-threatening. Predilife's specialized algorithms and predictive tools cater to the healthcare industry by aiding in personalized health management and enhancing decision-making processes for healthcare professionals and patients. As a significant player in the biotech field, Predilife S.A. contributes to the ongoing evolution of medical technology and personalized medicine, supporting the broad shift towards preventive healthcare measures.
The business is unprofitable at the operating level (-645.02% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 94.5% YoY with margins expanding 563.1pp.
ROIC dropped from -38.14% to -49.19%, capital efficiency is deteriorating. Negative free cash flow of -€4M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
€618K
▲ +94.5% YoY
Net Income (TTM)
€199M
▲ +4810.5% YoY
Op. Margin
-645.02%
▲ +563.1pp YoY
ROIC
-49.19%
▼ -11.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€4M
▲ +12.8% YoY
Op. Cash Flow (TTM)
-€4M
▲ +11.9% YoY
Net Debt
€4M
Cash & Equiv.
€1M
3Y CAGR: +63.0%
Continue Research